sarafloxacin has been researched along with cefotaxime in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bailer, R; Chu, DT; Fernandes, PB; Hanson, CW; Stamm, JM; Vojtko, C | 1 |
| Black, WA; Bowie, WR; Boyd, J; Chan, DG; Shaw, CE | 1 |
2 other study(ies) available for sarafloxacin and cefotaxime
| Article | Year |
|---|---|
In vitro evaluation of A-56619 (difloxacin) and A-56620: new aryl-fluoroquinolones.
Topics: Anti-Infective Agents; Aztreonam; Bacteria; Cefotaxime; Ciprofloxacin; Drug Combinations; Enterobacteriaceae; Escherichia coli; Fluoroquinolones; Gentamicins; Haemophilus influenzae; Half-Life; Humans; Imipenem; Microbial Sensitivity Tests; Neisseria gonorrhoeae; Norfloxacin; Penicillins; Piperacillin; Piperazines; Pseudomonas aeruginosa; Quinolines; Staphylococcus aureus; Streptococcus; Thienamycins | 1986 |
In vitro activity of difloxacin hydrochloride (A-56619), A-56620, and cefixime (CL 284,635; FK 027) against selected genital pathogens.
Topics: Anti-Bacterial Agents; Bacteria; Cefixime; Cefotaxime; Chlamydia trachomatis; Ciprofloxacin; Female; Fluoroquinolones; Gardnerella vaginalis; Genitalia; Humans; Male; Microbial Sensitivity Tests; Neisseria gonorrhoeae | 1986 |